Clinical trials: Nonalcoholic Steatohepatitis
NAFLD
Polyunsaturated Fatty Acids in Patients With NAFLD.
Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months.
- Trial name
- NCT02647294
- Testing
- Maxicor
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- General University Hospital, Prague
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
Management of risk factors is the primary approach to prevent cardiovascular disease (CVD). In this regard the accurate scoring of disease risk is fundamental.
- Trial name
- Endo-NAFLD (NCT06392828)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- IMDEA Food
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
NAFLD Primary Care
Non-alcoholic fatty liver disease (NAFLD) is with 25% the most prevalent liver disorder in Western society and is associated with overweight, obesity, metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), cardiovascular…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases, Type2 Diabetes, Metabolic Syndrome
- Trial name
- NCT04918732
- Testing
- FibroScan
- Where
- Netherlands
- Volunteers
- 1,470 people
- Sponsor
- Maastricht University
Non-alcoholic Steatohepatitis (NASH)
Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D
Test the efficacy of vitamin D to improve non-alcoholic steatohepatitis with regard to biochemical and histological parameters. Trial with medicinal product
- Trial name
- NCT01571063
- Testing
- Vitamin D3
- Where
- 2 sites in Switzerland
- Volunteers
- 22 people
- Sponsor
- University of Zurich
NAFLD
Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis.
- Trial name
- NAFLD (NCT03587298)
- Testing
- Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by…
- Trial name
- FLINT (NCT01265498)
- Testing
- obeticholic acid
- Where
- 9 sites in United States
- Volunteers
- 283 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fatty Liver, Fatty Liver, Alcoholic
Fatty Liver Disease Collaborative Research in China
A multi-center, prospective cohort study on the natural history of fatty liver disease in China
- Conditions
- Fatty Liver, Fatty Liver, Alcoholic, Non-alcoholic Fatty Liver Disease
- Trial name
- FLDCR (NCT02391168)
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Fatty Liver and Alcoholic Liver Disease Study Group, China
Cardiovascular Diseases, Metabolic Syndrome
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as…
- Conditions
- Cardiovascular Diseases, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease
- Trial name
- RESET (NCT06211868)
- Testing
- Digital wearable and AI-human symbiotic lifestyle intervention
- Where
- Singapore
- Volunteers
- 3,000 people
- Sponsor
- National University Hospital, Singapore
Nonalcoholic Steatohepatitis
Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, in combination with diet and exercise improve the histological results (steatosis, necro-inflammatory activity and fibrosis) in comparison with…
- Trial name
- NCT00509418
- Testing
- Viusid, Hypocaloric Diet with controlled exercise
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
Effects of VLCKD in Metabolic Syndrome
VLCKD has showed to be an impactful diet on several metabolism aspects and has proven to be useful for preventing and treating diabetes mellitus type 2, overweight, chronic inflammation and fatty liver.
- Conditions
- Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- KETO-MI (NCT05275608)
- Testing
- VLCKD diet with replacing meals, Hypocaloric mediterranean Diet
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Non-Alcoholic Fatty Liver Disease
A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver Health
A randomized, double blind, placebo controlled clinical trial to evaluate the efficacy and safety of MXP22 on liver health
- Trial name
- NCT05808049
- Testing
- MXP22 (Probiotic and antioxidant capsule)
- Where
- 2 sites in India
- Volunteers
- 60 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
NAFLD, Nonalcoholic Fatty Liver
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United…
- Conditions
- NAFLD, Nonalcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT05364684
- Testing
- LUM-201
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Healthy
Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD
The purpose of this study is to estimate the prevalence of genetic variants associated with liver disease in participants who are known, or are likely to have NAFLD.
- Trial name
- NCT04494360
- Testing
- No intervention
- Where
- 3 sites in United States
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Non-Alcoholic Fatty Liver Disease
Probiotics in NASH Patients - PROBILIVER TRIAL
Non-alcoholic Fatty Liver Disease (NAFLD) is characterized by excessive accumulation of lipids in hepatocytes, not associated with alcohol consumption and ranges from hepatic steatosis to steatohepatitis, a form that can progress…
- Trial name
- NASH (NCT03467282)
- Testing
- Probiotic
- Where
- Brazil
- Volunteers
- 46 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Non-Alcoholic Fatty Liver Disease
Calisthenics Versus High Intensity Interval Training in NAFL
According to sample size calculation and after achieving the inclusion criteria, sixty patients with non-alcoholic fatty liver (NAFL) of both genders will be enrolled in this study and their ages will be ranged from30s-40s; they…
- Trial name
- NCT06032650
- Testing
- Calisthenics exercise and High intensity interval training
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
NAFLD
Echocardiographic Findings as Markers of Subclinical Cardiac Dysfunction in Patients With Non-Alcoholic Fatty Liver Disease
The investigators aim to evaluate patients with NAFLD for early echocardiographic signs of myocardial dysfunction and if there is any correlation between the degree of steatosis or fibrosis and the degree of myocardial…
- Trial name
- NCT06130202
- Testing
- Echocardiographic findings
- Volunteers
- 165 people
- Sponsor
- Assiut University
NASH - Nonalcoholic Steatohepatitis, NAFLD
Characterization of the Platelet Inflammatory Response in NAFL and NASH
The primary objective of the study is to identify which features of platelet activation promote the inflammatory response that underlies the progression from NAFL to NASH. Therefore, the investigators plan: 1.
- Trial name
- NCT05128253
- Testing
- High fat meal in a subset of patients with NAFL or NASH
- Where
- 2 sites in Italy
- Volunteers
- 44 people
- Sponsor
- Stefania Basili
COVID-19
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
A prospective, longitudinal, observational cohort study looking at patients following COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury.
- Trial name
- COVERSCAN (NCT04369807)
- Testing
- Outpatient MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 693 people
- Sponsor
- Perspectum
Non-alcoholic Steatohepatitis
First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease
This is a Phase 1a/1b, randomised, double-blind, placebo-controlled single- and multiple-ascending dose study to evaluate the safety, tolerability, PK, and PD of GM-60106 in healthy adult male and female participants and…
- Trial name
- NCT05517564
- Testing
- GM-60106
- Where
- 2 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- JD Bioscience Inc.
Non Alcoholic Fatty Liver Disease
Mastiha Treatment for Obese With NAFLD Diagnosis
NAFLD/NASH is one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients.
- Trial name
- MAST4HEALTH (NCT03135873)
- Testing
- Mastiha
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Harokopio University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.